|
|
Substance Name: Brentuximab vedotin [USAN:INN]
RN: 914088-09-8
UNII: 7XL5ISS668
Notes
- Consists of cAC10 conjugated to monomethylauristatin E.
NCI: An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker ... (NCI Thesaurus) - Immunoconjugate that consists of the chimeric monoclonal anti - CD30 ANTIGEN antibody cAC-10 conjugated to monomethyl auristatin E. It is used for the treatment of LYMPHOMA.
Molecular Formula
- Unspecified
Molecular Weight
- 1349.7134
Classification Codes
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immunologic Factors
- Immunotoxins
- Noxae
- Treatment of Hodgkin's Lymphoma, CD30-Positive Hematologic Malignancies
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Names and Synonyms
Name of Substance
- Brentuximab vedotin [USAN:INN]
MeSH Heading
- Brentuximab vedotin
Synonyms
- Adcetris
- Anti-CD30 ADC SGN-35
- Anti-CD30 antibody-drug conjugate SGN-35
- Antibody-drug conjugate SGN-35
- Brentuximab Vedotin
- cAC10-vcMMAE
- SGN 35
- SGN-35
- UNII-7XL5ISS668
Systematic Name
- Immunoglobulin G1, anti-(human CD30 (antigen)) (human-mouse monoclonal cAC10 gamma1-chain), disulfide with human-mouse monoclonal cAC10 kappa-chain, dimer, complex with N-(((4-((N-(6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl)-L-valyl-N5-(aminocarbonyl)-L-ornithyl)amino)phenyl)methoxy)carbonyl)-N-methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1-methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-2-methoxy-1-((1S)-1-ethylpropyl)-4-oxobutyl)-N-methyl-L-valinamide
Registry Numbers
CAS Registry Number
- 914088-09-8
FDA UNII
- 7XL5ISS668
System Generated Number
- 0914088098